Anavex Life Sciences Corp (AVXL)

[JB3729]

Regarding the Lincoln Park Shelf Offering and funding an emerging biotech in general -

I would love to see a live debate between Adam F., SA author, and CEO Missling.

This is what Missling brings to the table -

Christopher U. Missling, MS, PhD, MBA

Dr. Missling, President and CEO of Anavex™, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.

The debate would be even more satisfying if the posters that came on here and challenged CEO Missling's LP decision joined the short's mouthpieces mentioned above.